Venture capital

China-US biotech firm closes $80m Series B funding

Sino-US trade tensions have not discouraged Korean investors from China's booming biotech industry as the cancer immunology specialist completes its Series B funding.
June 10, 2019

Shanghai and Boston-based oncology therapy provider Oncologie has raised $80 million Series B funding from Chinese and Korean investors.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media